What question did this study set out to answer?

The research aims to explore the role of ERBB3 in limiting the effectiveness of regorafenib in HCC after TKI therapies.

January 22, 2026Open Access

ERBB3 blockade sensitizes HCC to regorafenib after first-line TKI resistance by inhibiting HIF1A-ABCB1 signaling

Key Points

The research aims to explore the role of ERBB3 in limiting the effectiveness of regorafenib in HCC after TKI therapies.
Evaluated the impact of ERBB3 blockade on regorafenib efficacy
Compared responses in HCC models with prior TKI resistance
Analyzed HIF1A-ABCB1 signaling pathways
ERBB3 was identified as a significant resistance factor to regorafenib.
Inhibition of ERBB3 increased sensitivity to regorafenib after TKI resistance.
Disruption of HIF1A-ABCB1 signaling correlated with enhanced drug response.

Abstract

This study revealed that ERBB3 was a key resistance factor driving limited efficacy to sequential regorafenib, but also an effective therapeutic target whose inhibition enhanced regorafenib sensitivity after sorafenib or lenvatinib resistance.

Read Full Paperexternally

Bookmark

View Full Paper

Cite This Study

Tao et al. (Tue,) studied this question.

synapsesocial.com/papers/6971bdcf642b1836717e27ad https://doi.org/https://doi.org/10.3350/cmh.2025.0972

Bookmark

View Full Paper